Drug Profile
SB 218842
Alternative Names: TidembersatLatest Information Update: 27 Mar 2001
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Antimigraines
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Migraine
Most Recent Events
- 27 Mar 2001 Discontinued-I for Migraine in United Kingdom (Unknown route)
- 24 Jan 2001 SmithKline Beecham has merged with Glaxo Wellcome to form GlaxoSmithKline
- 02 Oct 1998 Phase-I clinical trials for Migraine in United Kingdom (Unknown route)